Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

OBJECTIVE: This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) cohort. RESEARCH DESIGN AND METHODS: LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Care
Main Authors: Nauck, Michael A., Jensen, Thomas Jon, Rosenkilde, Carina, Calanna, Salvatore, Buse, John B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2018
Assuntos:
Emerging Therapies: Drugs and Regimens
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463597/
https://ncbi.nlm.nih.gov/pubmed/29898902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc17-1825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados